What IGF-1 DES is
IGF-1 DES, or des(1–3)IGF-I, is a truncated 67-amino-acid analogue missing the first three amino acids of native IGF-1.[1] It is not mecasermin and has no FDA-approved product, indication, or dose.
The evidence is laboratory and animal research
Biochemical work found that IGF-binding proteins inhibited native IGF-I and IGF-II differently from des(1–3)IGF-I.[2] Animal research found more potent and prolonged glucose-lowering effects for IGF-I variants with poor binding-protein affinity.[3] These findings do not establish muscle gain, recovery, fat loss, anti-aging benefit, or a safe human dose.
Human safety is undefined
No controlled human safety program or regulator-reviewed adverse-reaction table exists for IGF-1 DES. Hypoglycemia is biologically plausible and appeared strongly in animal work, while product identity, sterility, immune response, abnormal tissue growth, interactions, pregnancy use, and long-term effects remain unresolved.
The Increlex label documents serious risks for mecasermin, including hypoglycemia and neoplasia warnings, but those product-specific data cannot be converted into incidence estimates for DES.[4]
Regulatory and sport status
IGF-1 DES is unapproved in the United States. The narrow approval of mecasermin for specified pediatric growth failure does not extend to DES.[4] IGF-1 analogues are prohibited in tested sport.[5] Teloryx does not publish a DES dose, cycle, stack, or reconstitution recipe.